In vivo assessment of a delayed release formulation of larazotide acetate indicated for celiac disease using a porcine model

There is no FDA approved therapy for the treatment of celiac disease (CeD), aside from avoidance of dietary gluten. Larazotide acetate (LA) is a first in class oral peptide developed as a tight junction regulator, which is a lead candidate for management of CeD. A delayed release formulation was tes...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Enomoto, Hiroko, Yeatts, James, Carbajal, Liliana, Krishnan, B. Radha, Madan, Jay P., Laumas, Sandeep, Blikslager, Anthony T., Messenger, Kristen M.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8041193/
https://ncbi.nlm.nih.gov/pubmed/33844694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0249179
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados